Addressing solutions in the rare disease community for more than 400 million people worldwide has been a significant challenge for industry, advocacy groups and rare disease families alike.
In 2023, Amgen collaborated closely with 44 rare disease organizations who were recipients of the #RAREis Global Advocate Grant program, representing 14 countries across the globe. Through a survey and a live summit, the group shared the biggest issues their communities face as well as opportunities to accelerate progress. The new white paper sharing their feedback was published today and can be downloaded here.
The 2024 #RAREis White Paper highlights the key issues facing rare disease advocates and demonstrates how a global approach to collaborations and insights sharing across disease states can fuel progress for the rare disease community at large.
While many challenges in rare disease are specific to the rare condition itself, other critical issues face many rare disease states, including:
The themes identified above are all areas of opportunity and ripe for change. The advocate participants identified meaningful learnings that can be implemented by anyone supporting the rare disease community to make a difference:
The launch of the white paper also coincides with the kickoff of the 2024 #RAREis Global Advocate Grant application opening. Applications for this year’s grant program are open until May 31.
Learn more about how the #RAREis Global Advocate Grant program has engaged advocates from around the world, providing grant support at the micro level to generate macro momentum and have your advocacy organization apply for funding today!